FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

Source: 
Medical Marketing and Media
snippet: 


The Food and Drug Administration approved Tofersen, an investigational drug developed by Biogen and Ionis Pharmaceuticals, to treat a rare genetic form of amyotrophic lateral sclerosis (ALS) Tuesday afternoon.